Teva Pharmaceutical Industries Limited (NYSE:TEVA) Given Consensus Recommendation of “Moderate Buy” by Analysts

Teva Pharmaceutical Industries Limited (NYSE:TEVA) has been assigned an average rating of “Moderate Buy” from the eight brokerages that are currently covering the firm, Marketbeat.com reports. Two research analysts have rated the stock with a hold recommendation and six have assigned a buy recommendation to the company. The average twelve-month target price among brokerages that have issued ratings on the stock in the last year is $22.13.

Several analysts recently weighed in on the stock. Barclays lifted their price target on shares of Teva Pharmaceutical Industries from $25.00 to $28.00 and gave the company an “overweight” rating in a report on Wednesday, December 18th. Piper Sandler boosted their price target on shares of Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the company an “overweight” rating in a research report on Friday. StockNews.com cut Teva Pharmaceutical Industries from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, December 18th. Finally, JPMorgan Chase & Co. increased their target price on Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the stock a “neutral” rating in a research report on Monday, October 21st.

Insider Buying and Selling at Teva Pharmaceutical Industries

In related news, Director Roberto Mignone sold 286,000 shares of the company’s stock in a transaction dated Friday, December 20th. The shares were sold at an average price of $22.01, for a total value of $6,294,860.00. Following the transaction, the director now owns 695,000 shares in the company, valued at $15,296,950. The trade was a 29.15 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Christine Fox sold 19,388 shares of the stock in a transaction dated Wednesday, November 20th. The shares were sold at an average price of $16.87, for a total transaction of $327,075.56. Following the sale, the executive vice president now directly owns 44,104 shares in the company, valued at $744,034.48. This trade represents a 30.54 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.55% of the stock is owned by company insiders.

Institutional Trading of Teva Pharmaceutical Industries

Several institutional investors have recently added to or reduced their stakes in TEVA. Coronation Fund Managers Ltd. bought a new position in shares of Teva Pharmaceutical Industries during the second quarter valued at $1,334,000. American Century Companies Inc. raised its position in Teva Pharmaceutical Industries by 12.9% in the 2nd quarter. American Century Companies Inc. now owns 175,178 shares of the company’s stock worth $2,847,000 after buying an additional 20,026 shares during the last quarter. DekaBank Deutsche Girozentrale lifted its stake in Teva Pharmaceutical Industries by 8.6% during the 2nd quarter. DekaBank Deutsche Girozentrale now owns 78,319 shares of the company’s stock valued at $1,263,000 after acquiring an additional 6,192 shares during the period. Dai ichi Life Insurance Company Ltd boosted its holdings in shares of Teva Pharmaceutical Industries by 5.5% during the 2nd quarter. Dai ichi Life Insurance Company Ltd now owns 52,146 shares of the company’s stock valued at $847,000 after acquiring an additional 2,697 shares during the last quarter. Finally, Thoroughbred Financial Services LLC lifted its position in Teva Pharmaceutical Industries by 14.3% during the second quarter. Thoroughbred Financial Services LLC now owns 17,592 shares of the company’s stock valued at $285,000 after purchasing an additional 2,200 shares during the period. 54.05% of the stock is currently owned by hedge funds and other institutional investors.

Teva Pharmaceutical Industries Trading Up 1.3 %

NYSE TEVA opened at $21.97 on Monday. The stock has a market cap of $24.89 billion, a P/E ratio of -25.84, a price-to-earnings-growth ratio of 1.06 and a beta of 0.73. Teva Pharmaceutical Industries has a fifty-two week low of $10.86 and a fifty-two week high of $22.80. The stock has a 50 day simple moving average of $19.24 and a two-hundred day simple moving average of $18.20. The company has a debt-to-equity ratio of 2.57, a quick ratio of 0.61 and a current ratio of 0.89.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.